Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central anxious program, conolidine modulates alternate molecular targets. A Science Advancements review located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://abdulj541fhi3.blogsvila.com/profile